Surveillance of population immunity against infectious diseases is critical for pandemic management and risk assessment of future outbreaks. However, current serological tests fall short in accurately identifying immunity profiles from diverse populations. We present a label-free, rapid, multiplexed, and variant-sensitive nanoplasmonic biosensor to quantify antibodies against multiple SARS-CoV-2 antigens from small human blood samples. We combined a machine learning model with antigen-specific antibody patterns measured from four different cohorts with known COVID-19 immunity. Subsequently, we tested our model on 100 blind human samples and determine that our findings are consistent with public epidemiological data showing that our nanobiosensor can help monitor population health during a pandemic.
|